Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glimepiride + ketotifen is a combination of two small molecule drugs, glimepiride and ketotifen. Glimepiride is a sulfonylurea antidiabetic agent that stimulates insulin secretion from pancreatic beta cells, thereby lowering blood glucose levels. Ketotifen is an antihistamine and mast cell stabilizer that acts as a non-competitive antagonist of the histamine H1 receptor and inhibits the release of inflammatory mediators from mast cells. This combination has been studied for its potential to improve glycemic control and reduce inflammation in obese patients with type 2 diabetes mellitus (T2DM), based on evidence suggesting that mast cell stabilization may help mitigate obesity-induced insulin resistance[2]. The co-administration of these agents has shown beneficial effects on glycemic parameters and inflammatory biomarkers in clinical studies[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glimepiride + ketotifen.